Spatial alignment of Computed Tomography (CT) data sets is often required in numerous medical applications and it is usually achieved by applying conventional exhaustive registration techniques, which are mainly based on the intensity of the subject data sets. Those techniques consider the full range of data points composing the data, thus negatively affecting the required processing time. Alternatively, alignment can be performed using the correspondence of extracted data points from both sets. Moreover, various geometrical characteristics of those data points can be used, instead of their chromatic properties, for uniquely characterizing each point, by forming a specific geometrical descriptor. This paper presents a comparative study reviewing variations of geometry-based, descriptor-oriented registration techniques, as well as conventional, exhaustive, intensity-based methods for aligning three-dimensional (3D) CT data pairs. In this context, three general image registration frameworks were examined: a geometry-based methodology featuring three distinct geometrical descriptors, an intensity-based methodology using three different similarity metrics, as well as the commonly used Iterative Closest Point algorithm. All techniques were applied on a total of thirty 3D CT data pairs with both known and unknown initial spatial differences. After an extensive qualitative and quantitative assessment, it was concluded that the proposed geometry-based registration framework performed similarly to the examined exhaustive registration techniques. In addition, geometry-based methods dramatically improved processing time over conventional exhaustive registration.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.compbiomed.2015.12.013 | DOI Listing |
Gene Ther
January 2025
Nantes Université, CHU Nantes, INSERM, TaRGeT-Translational Research in Gene Therapy, UMR1089, F-44200, Nantes, France.
The liver is a unique organ where immunity can be biased toward ineffective response notably in the context of viral infections. Chronic viral hepatitis depends on the inability of the T-cell immune response to eradicate antigen. In the case of recombinant Adeno-Associated-Virus, used for therapeutic gene transfer, conflicting reports describe tolerance induction to different transgene products while other studies have shown conventional cytotoxic CD8 T cell responses with a rapid loss of transgene expression.
View Article and Find Full Text PDFSignal Transduct Target Ther
January 2025
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Biochemistry and Molecular Biology, Fourth Military Medical University, Xi'an, Shaanxi, China.
The excessive cytokine release and limited persistence represent major challenges for chimeric antigen receptor T (CAR-T) cell therapy in diverse tumors. Conventional CARs employ an intracellular domain (ICD) from the ζ subunit of CD3 as a signaling module, and it is largely unknown how alternative CD3 chains potentially contribute to CAR design. Here, we obtained a series of CAR-T cells against HER2 and mesothelin using a domain comprising a single immunoreceptor tyrosine-based activation motif from different CD3 subunits as the ICD of CARs.
View Article and Find Full Text PDFJ Chem Inf Model
January 2025
Department of Computer Science, School of Computing, Institute of Science Tokyo, Yokohama 226-8501, Japan.
Accurate prediction of the difference in binding free energy between compounds is crucial for reducing the high costs associated with drug discovery. Relative binding free energy perturbation (RBFEP) calculations are effective for small structural changes; however, large topological changes pose significant challenges for calculations, leading to high errors and difficulties in convergence. To address such issues, we propose a new approach─PairMap─that focuses on introducing appropriate intermediates for complex transformations between two input compounds.
View Article and Find Full Text PDFCancer Treat Rev
December 2024
Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli, Italy. Electronic address:
Within the expanding therapeutic landscape for breast cancer (BC), metastatic breast cancer (MBC) remains virtually incurable and tend to develop resistance to conventional treatments ultimately leading to metastatic progression and death. Cellular immunotherapy (CI), particularly chimeric antigen receptor-engineered T (CAR-T) cells, has emerged as a promising approach for addressing this challenge. In the wake of their striking efficacy against hematological cancers, CAR-T cells have also been used where the clinical need is greatest - in patients with aggressive BCs.
View Article and Find Full Text PDFCancers (Basel)
December 2024
Department of Microbiology, Immunology & Molecular Genetics, David Geffen School of Medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095, USA.
The treatment of cancers with immunotherapies has yielded significant milestones in recent years. Amongst these immunotherapeutic strategies, the FDA has approved several checkpoint inhibitors (CPIs), primarily Anti-Programmed Death-1 (PD-1) and Programmed Death Ligand-1/2 (PDL-1/2) monoclonal antibodies, in the treatment of various cancers unresponsive to immune therapeutics. Such treatments resulted in significant clinical responses and the prolongation of survival in a subset of patients.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!